Evaxion Granted 180-Day Compliance Extension by Nasdaq
Evaxion Biotech A/S (NASDAQ: EVAX), a leading clinical-stage TechBio company known for its innovative AI-Immunology™ powered vaccines, is making strides in its efforts to meet Nasdaq's minimum equity requirements. After a productive hearing with Nasdaq's panel, the company has been awarded a 180-day extension to demonstrate compliance regarding stockholder’s equity.
Strengthening Financial Position
Recently, Evaxion successfully restored its equity above the Nasdaq's $2.5 million minimum requirement. This achievement was made possible through the exercise of prefunded warrants and the sale of shares via its ATM facility, which collectively added approximately $7.8 million to its financial resources. With this influx of cash, Evaxion has extended its financial runway to support operations well into the fourth quarter of 2025.
Ongoing Discussions with EIB
Further enhancing its financial outlook, Evaxion is engaged in discussions with the European Investment Bank (EIB) regarding the conversion of a significant portion of its loan into equity. The conversion is anticipated to be completed in the first quarter of 2025, thereby potentially boosting the company's equity by $3.7 million. This move aligns with Evaxion’s proactive strategy to maintain its Nasdaq listing while fostering growth and stability.
Path to Compliance and Future Goals
The extension from Nasdaq provides Evaxion until the forthcoming months to solidify its compliance with the required equity standard. With a clear plan in place, the company is optimistic about maintaining its Nasdaq listing and continuing its trajectory of growth. The management has expressed confidence in their ability to strengthen their equity position even further through ongoing business development initiatives.
CEO's Vision for Growth
Christian Kanstrup, CEO of Evaxion, conveyed enthusiasm regarding the extension, stating, “We welcome the opportunity to continue working towards formal compliance with Nasdaq’s equity requirement. Our current equity and cash positions have significantly improved, and we are exploring additional strategies to reinforce our stockholder’s equity.” Kanstrup highlighted the growing interest from potential partners and expressed confidence in achieving at least two new business development agreements in the upcoming year.
The Road Ahead for Evaxion
Despite the challenges ahead, including the need for continued compliance with Nasdaq's directive, Evaxion is poised for growth. The company’s proactive measures showcase its commitment to not only meet regulatory requirements but also to enhance its overall business strategy. The dynamics of the tech-biotech sector offer promising opportunities, and with the power of AI driving its innovations, Evaxion is at the forefront of significant advancements in the industry.
Background on Nasdaq Compliance Issues
This 180-day compliance extension follows Evaxion's previous challenges in maintaining stockholders’ equity, which led to a deficiency letter from Nasdaq months earlier. After presenting a comprehensive plan for regaining compliance, the company has demonstrated significant progress in strengthening its financial standing, resulting in this favorable decision by Nasdaq.
Contact Information
If you have inquiries or require more details, you can reach out to:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Frequently Asked Questions
What does the compliance extension from Nasdaq mean for Evaxion?
The compliance extension allows Evaxion additional time to demonstrate that it meets the minimum stockholder’s equity requirement to maintain its Nasdaq listing.
How has Evaxion restored its equity?
Evaxion restored its equity by exercising prefunded warrants and sales of its shares through its ATM-facility, amounting to $7.8 million.
What are Evaxion's upcoming financial strategies?
The company plans to convert part of its European Investment Bank loan into equity and is actively pursuing additional business development agreements.
Who is leading Evaxion?
Christian Kanstrup is the CEO of Evaxion, guiding the company's strategic direction and efforts to secure compliance and growth.
What is Evaxion's area of expertise?
Evaxion specializes in AI-driven immunotherapy solutions, focusing on developing innovative vaccines for various diseases, including cancer and viral infections.
